NeuroPace (NPCE) – Investment Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for NeuroPace (NASDAQ: NPCE):

• 12/29/2025 – NeuroPace had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/16/2025 – NeuroPace had its price target raised by analysts at UBS Group AG from $18.00 to $22.00. They now have a “buy” rating on the stock.
• 12/15/2025 – NeuroPace had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/10/2025 – NeuroPace had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $20.00. They now have an “overweight” rating on the stock.
• 12/9/2025 – NeuroPace had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/9/2025 – NeuroPace had its “buy” rating reaffirmed by analysts at UBS Group AG. They now have a $18.00 price target on the stock.
• 11/5/2025 – NeuroPace had its “outperform” rating reaffirmed by analysts at Leerink Partners. They now have a $19.00 price target on the stock.
• 11/5/2025 – NeuroPace had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $16.00 price target on the stock.
• 11/5/2025 – NeuroPace had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $18.00. They now have an “overweight” rating on the stock.
• 11/5/2025 – NeuroPace had its price target raised by analysts at Wells Fargo & Company from $15.00 to $16.00. They now have an “overweight” rating on the stock.

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.